LUPIN.NS Lupin Limited
P/E
18.247969
Forward P/E
21.539267
Price/Sales
3.359542
Beta
0.182
Div Yield
0.008199999999999999%
Market Cap
--
Company Analysis
Latest News
Lupin expands European eye-care reach with €75 million Visus licensing deal
Lupin Limited subsidiary VISUfarma B.V. entered an exclusive licensing agreement with Visus Therapeutics Inc. to commercialize YUVEZZI. The partnership covers...
Lupin Secures USFDA Approval for Generic Wakix, Ending Patent Dispute
Lupin Limited received final USFDA approval for its Pitolisant Tablets. The approval covers the 4.45 mg and 17.8 mg dosage strengths. This medication is a...
Lupin Wins FDA Approval for Lokelma Generic, Targeting $568 Million Market
Lupin Limited received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral...
🔴 Lupin is trading 4% down today after Q1 FY27 EPS missed estimates
Lupin is trading at INR 2267.20 (-4.07%) after investors weighed a modest Q1 FY27 earnings miss and cautious near-term U.S. outlook. • Q1 revenue rose 33%,...